Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 2
2013 1
2015 2
2016 1
2017 1
2018 4
2019 10
2020 8
2021 5
2022 9
2023 6
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

39 results

Results by year

Filters applied: . Clear all
Page 1
Relapsed and refractory multiple myeloma: A systematic review and network meta-analysis of the efficacy of novel therapies.
Minakata D, Fujiwara SI, Yokoyama D, Noguchi A, Aoe S, Oyama T, Koyama S, Murahashi R, Nakashima H, Hyodo K, Ikeda T, Kawaguchi SI, Toda Y, Ito S, Nagayama T, Mashima K, Umino K, Morita K, Ashizawa M, Yamamoto C, Hatano K, Sato K, Ohmine K, Kanda Y. Minakata D, et al. Among authors: nagayama t. Br J Haematol. 2023 Mar;200(6):694-703. doi: 10.1111/bjh.18654. Epub 2023 Jan 20. Br J Haematol. 2023. PMID: 36661264 Review.
Antibody-mediated pathogenesis of chronic GVHD through DBY/HLA class II complexes and induction of a GVL effect.
Umino K, Morita K, Ikeda T, Kawaguchi SI, Nagayama T, Ito S, Minakata D, Ashizawa M, Yamamoto C, Hatano K, Sato K, Ohmine K, Fujiwara SI, Kimura SI, Kako S, Doki N, Ozawa Y, Mori Y, Eto T, Hiramoto N, Nakamae H, Kanda J, Ichinohe T, Atsuta Y, Nakasone H, Morishima S, Kanda Y. Umino K, et al. Among authors: nagayama t. Blood. 2023 Sep 14;142(11):1008-1021. doi: 10.1182/blood.2023019799. Blood. 2023. PMID: 37363859
Risk factors for high-dose methotrexate-induced nephrotoxicity.
Kawaguchi S, Fujiwara SI, Murahashi R, Nakashima H, Matsuoka S, Ikeda T, Toda Y, Ito S, Ban T, Nagayama T, Umino K, Minakata D, Nakano H, Yamasaki R, Ashizawa M, Yamamoto C, Hatano K, Sato K, Oh I, Ohmine K, Kanda Y. Kawaguchi S, et al. Among authors: nagayama t. Int J Hematol. 2021 Jul;114(1):79-84. doi: 10.1007/s12185-021-03132-8. Epub 2021 Mar 20. Int J Hematol. 2021. PMID: 33743109
Daratumumab in first-line therapy is cost-effective in transplant-eligible patients with newly diagnosed myeloma.
Yamamoto C, Minakata D, Koyama S, Sekiguchi K, Fukui Y, Murahashi R, Nakashima H, Matsuoka S, Ikeda T, Kawaguchi SI, Toda Y, Ito S, Nagayama T, Umino K, Nakano H, Morita K, Yamasaki R, Ashizawa M, Ueda M, Hatano K, Sato K, Ohmine K, Fujiwara SI, Kanda Y. Yamamoto C, et al. Among authors: nagayama t. Blood. 2022 Aug 11;140(6):594-607. doi: 10.1182/blood.2021015220. Blood. 2022. PMID: 35580269 Free PMC article.
Cost-Effectiveness of Anti-BCMA Chimeric Antigen Receptor T Cell Therapy in Relapsed/Refractory Multiple Myeloma.
Yamamoto C, Minakata D, Yokoyama D, Furuki S, Noguchi A, Koyama S, Oyama T, Murahashi R, Nakashima H, Ikeda T, Kawaguchi SI, Hyodo K, Toda Y, Ito S, Nagayama T, Umino K, Morita K, Ashizawa M, Ueda M, Hatano K, Sato K, Ohmine K, Fujiwara SI, Kanda Y. Yamamoto C, et al. Among authors: nagayama t. Transplant Cell Ther. 2024 Jan;30(1):118.e1-118.e15. doi: 10.1016/j.jtct.2023.10.001. Epub 2023 Oct 5. Transplant Cell Ther. 2024. PMID: 37802181
Urine Xanthine Crystals in Hematologic Malignancies with Tumor Lysis Syndrome.
Ito S, Fujiwara SI, Yoshizawa T, Hayatsu K, Sekiguchi K, Murahashi R, Nakashima H, Matsuoka S, Ikeda T, Toda Y, Kawaguchi S, Nagayama T, Umino K, Minakata D, Nakano H, Morita K, Yamasaki R, Ashizawa M, Yamamoto C, Hatano K, Sato K, Ohmine K, Kanda Y. Ito S, et al. Among authors: nagayama t. Intern Med. 2022 Nov 1;61(21):3271-3275. doi: 10.2169/internalmedicine.9332-22. Epub 2022 Apr 2. Intern Med. 2022. PMID: 35370238 Free PMC article.
Clinical association between thyroid disease and immune thrombocytopenia.
Ito S, Fujiwara SI, Murahashi R, Nakashima H, Matsuoka S, Ikeda T, Kawaguchi SI, Toda Y, Ban T, Nagayama T, Umino K, Minakata D, Morita K, Nakano H, Yamasaki R, Ashizawa M, Yamamoto C, Hatano K, Sato K, Oh I, Ohmine K, Kanda Y. Ito S, et al. Among authors: nagayama t. Ann Hematol. 2021 Feb;100(2):345-352. doi: 10.1007/s00277-020-04343-5. Epub 2020 Nov 9. Ann Hematol. 2021. PMID: 33165625 Clinical Trial.
Clinical interaction between dexamethasone and aprepitant in chemotherapy for lymphoma.
Hatano K, Fujiwara SI, Umino K, Ikeda T, Nakano H, Mashima K, Kawaguchi SI, Ito S, Toda Y, Nagayama T, Minakata D, Yamasaki R, Morita K, Yamamoto C, Ashizawa M, Sato K, Ueda M, Ohmine K, Kanda Y. Hatano K, et al. Among authors: nagayama t. Ann Hematol. 2022 Jun;101(6):1211-1216. doi: 10.1007/s00277-022-04832-9. Epub 2022 Apr 11. Ann Hematol. 2022. PMID: 35403851
Effect of cumulative daunorubicin dose on cardiotoxicity after allogeneic stem cell transplantation.
Fujiwara SI, Murahashi R, Nakashima H, Matsuoka S, Ikeda T, Toda Y, Ito S, Kawaguchi SI, Nagayama T, Umino K, Minakata D, Morita K, Nakano H, Ashizawa M, Yamamoto C, Hatano K, Sato K, Ohmine K, Kanda Y. Fujiwara SI, et al. Among authors: nagayama t. Leuk Res. 2022 Oct;121:106951. doi: 10.1016/j.leukres.2022.106951. Epub 2022 Sep 12. Leuk Res. 2022. PMID: 36115066
Dimethyl fumarate ameliorates graft-versus-host disease by inhibiting T-cell metabolism and immune responses through a reactive oxygen species-dependent mechanism.
Mashima K, Sato K, Ikeda T, Izawa J, Takayama N, Hayakawa H, Kawaguchi SI, Nakano H, Nagayama T, Umino K, Morita K, Tominaga K, Endo H, Kanda Y. Mashima K, et al. Among authors: nagayama t. Br J Haematol. 2022 Jun;197(6):e78-e82. doi: 10.1111/bjh.18082. Epub 2022 Feb 15. Br J Haematol. 2022. PMID: 35170051 No abstract available.
39 results